Introduction
============

It is widely accepted that three-dimensional (3D) *in vitro* cultures simulate the *in vivo* situation better than two-dimensional ones. Although micromass culture is considered a useful tool for studies of chondrogenesis, it is not suitable for cell therapy [@B1]. Scaffolds can, however, provide an appropriate 3D environment for cell viability and proliferation, cell differentiation and maintenance of a specific phenotype [@B2].

Tissue Engineering using biodegradable scaffolds, cells and cell factors has evolved into a multidisciplinary field with an aim to develop biological substitutes with biochemical, structural, morphological and functional properties similar to native cartilage for subsequent use for *in vivo* treatment [@B3]. The most important issue in Tissue Engineering is the selection of cell type and optimal scaffold.

Most studies have tested growth and differentiation of cells on various scaffolds but have not placed the constructs inside a native cartilage environment or taken the host tissue into account [@B4]. *In vitro* testing is easier than *in vivo* testing for obtaining standardized and quantifiable information about cell cytotoxicity, proliferation and differentiation capacity [@B5]. This model allows us to analyze human cartilage samples from a single donor using different study variables and to test different constructs in an *in vitro* native environment. In our study, this model was used to test the repair capacity of different constructs.

Materials and Methods
=====================

Isolation and culture of bone marrow stromal cells
--------------------------------------------------

Each donor in the study gave informed consent according to the guidelines of the local ethics committee and principles of Declaration of Helsinki. This study was approved by the Ethics Committee of Clinical Investigation of Galicia (Santiago de Compostela, Spain).

Bone marrow cells were obtained from three hip fracture patients who underwent total hip replacement, as previously described [@B6]. Cells were extracted by washing the bone marrow with culture medium: Dulbecco´s Modified Eagle´s Medium (DMEM; Lonza, Spain) with 20% foetal bovine serum (LabClinics, Spain). The isolated cells were cultured in a 5% humidified CO~2~ atmosphere at 37ºC. The resultant cell suspension was cultured and expanded. We previously confirmed by characterization [@B6] that cells obtained by this method are hBMSCs.

Scaffolds
---------

Different Col scaffolds (Opocrin S.p.A., Modena, Italy) had been previously tested by our group [@B6], [@B7]. From those, scaffolds producing better chondrogenic hBMSC phenotypes, including type I collagen (Col I), Col I and heparan sulfate (Col I+HS), Col I and type II collagen (Col II) and HS (Col I+Col II+HS) and Col I and Col II and chondroitin sulfate (Col I+Col II+CHS) were selected. The hBMSCs were cultured on the surface of 4 mm-diameter sponges and incubated for 1 h at 37ºC. These constructs were used for the *in vitro* lesion model using chondrogenic medium: hMSC Chondrogenic Differentiation Bulletkit medium (Lonza, Spain) with 10ng/ml of human transforming growth factor β-3 (TGFβ-3, Prospec-Tany Technogene Ltd., Israel).

In vitro lesion model
---------------------

Cartilage samples were obtained from three patients who underwent total hip or knee replacement because of fracture or osteoarthritis (OA). The cartilage was sliced with a scalpel and 6mm biopsies were obtained using disposable biopsy punches (Kai Medical, Germany).

3 mm-Diameter lesions were made in human cartilage biopsies using a dental drill (Gebr. Brasseler Gmbh & Co. KQ, Germany) with a rotor (EWL K9, Germany). Over a two-month period, two experiments were performed:Non-IL1β Group: 2x10^5^ cells were seeded on scaffolds. These constructs were placed into the lesion and chondrogenic medium was added. The medium was changed every 3-4 days.IL1β Group: Cartilage biopsies with lesions were pre-treated with 10ng/ml of IL1β (Sigma, USA) for 24 hours. 2x10^5^ cells were seeded on scaffolds, the resulting sponge-constructs were introduced into the lesion and chondrogenic medium was added. The medium was changed every 3-4 days.

Following controls were included: defect without constructs, defect with scaffolds and without cells, and native cartilage without defect (Figure [S1](#SM0){ref-type="supplementary-material"}).

Histological analysis
---------------------

The resulting neotissue was evaluated histochemically using 4 µm-thick deparaffinized sections. These sections were then stained with hematoxylin and eosin (HE), and stained for collagen and proteoglycans (PGs) with Masson\'s trichrome (MT) or Safranin O (SO), respectively. The stained sections were examined using an optical microscope (Olympus BX61, USA) equipped with a digital camera (Olympus DP70, USA). Quantitative analyses of the SO staining were measured using ImageJ 1.48v (*National Institutes of Health, Bethesda, USA*). After the colour substraction of non-stained areas, the percentage of metachromatic areas was measured and expressed as mean±standard error.

To assess the quality of cartilage repair, the ICRS II histological scoring system [@B8] was used with some modifications to adapt it for analysis of *in vitro* cartilage repair. The neotissues formed were scored by three blind observers. Our modified score system comprised 7 out of the 14 parameters: "cell morphology" and "chondrocyte clustering" as well as "surface architecture" and the "basal integration" of the neotissue formed were observed by the HE staining; "tissue morphology" was assessed by analyzing the collagen fiber distribution with MT staining; the parameter to evaluate PG content was "matrix staining", which was assessed using SO staining; and, the "overall assessment" was the statistical mean of the values for all 6 parameters analyzed.

Further immunohistochemical analysis of Col I, Col II and aggrecan (Agg) was performed in samples with highest ICRS II score.

Results
=======

Controls and Non-IL1β model
---------------------------

Control constructs without cells did not show presence of neotissue formation and the scaffolds were not degraded (Figure [S1](#SM0){ref-type="supplementary-material"}, Ctrl w/o cells). Self-repair did not occur in the negative control (Figure [S1](#SM0){ref-type="supplementary-material"}, control lesion). In the Non-IL1β model, histochemistry after two months revealed that cells seeded on all scaffolds filled almost 100% of the lesion and that neotissues were integrated with the border of the lesion (Figure [1](#F1){ref-type="fig"}, H-E Non-IL). Scaffolds were almost fully degraded in this model, except the Col I+HS scaffold, and cellular density in all the grafts was higher (Figure [1](#F1){ref-type="fig"}, H-E Non-IL) than that in the native cartilage (Figure [S1](#SM0){ref-type="supplementary-material"}, positive control). Spindle- and round-shaped cell morphology was found in all neotissues.

Staining with MT showed the presence of Col in the ECM of all the constructs (Figure [1](#F1){ref-type="fig"}, H-E Non-IL), that was observably more homogeneous in the tissues of the Col I+Col II+HS constructs. The presence of PGs detected by SO staining (Figure [1](#F1){ref-type="fig"}, H-E Non-IL) was more metachromatic in the Col I+Col II+HS constructs (52.426±4.877) than in Col I (5.107±3.337), Col I+HS (23.406±6.189) and Col I+Col II+CHS (32.722±8.781) constructs.

By macroscopic ICRS II assessment of the Non-IL model, the repair score was between 44% and 47%, or fibrocartilage, for Col I, Col I+Col II+CHS and Col I+HS scaffolds. Col I+Col II+HS scaffolds showed a chondrogenic phenotype, 73%, or mixed firbrocartilage and hyaline cartilage on the ICRS II scale. This was confirmed by histological and immunohistochemical analysis that showed the presence of PGs and Col, being positive for Col II and Agg (Figure [2](#F2){ref-type="fig"}).

IL1β-treated model
------------------

In the IL1β model, HE staining showed neotissue formation within the lesion with fewer rounded cells than in the Non-IL1β model (Figure [1](#F1){ref-type="fig"}, H-E IL). The presence of PGs detected by SO staining (Figure [1](#F1){ref-type="fig"}, H-E IL) was more metachromatic in the Col I+Col II+CHS constructs (23.228±1.704) than in Col I (5.738±1.283), Col I+HS (5.107±2.435) and Col I+Col II+HS (20.973±6.849) constructs. These morphological changes with the loss of ECM components observed by SO and MT staining resulted in lowering of the ICRS II scores except those for the Col I+HS and Col I+Col II+CHS constructs (49%-43%, respectively) (Table [1](#T1){ref-type="table"}).

Discussion
==========

This model supposes an improvement compared with other 3D *in vitro* models.

Because cell phenotype and extracellular matrix (ECM) vary with cartilage depth [@B9], constructs, once implanted, are influenced by the native cell metabolism of each zone [@B10].

We found that cellular density in all the grafts was higher than in the native cartilage and, flattened-like undifferentiated cells were observed in all the scaffolds. The presence of undifferentiated hBMSCs or chondrocyte-like cells without zonal organization may be advantageous for Cartilage Engineering because immature tissue is capable of maturing when implanted in the joint [@B4].

Col I+Col II+HS scaffolds showed a fibrocartilage/hyaline cartilage phenotype, using the ICRS II scale. These results are similar to those obtained in a clinical study following microfracture treatment [@B11].

Chondrocytes implanted into focal or OA joint lesions were susceptible to native inflammation. Furthermore, problems with mechanics in OA and eventual loss of integrity, functionality and, long-term neotissue viability could be compromised [@B12]. Khan *et al.* found that a single short catabolic pulse of IL1β followed by post-culture anabolic conditions is sufficient to generate mechanically robust, integrative cartilage repair [@B13]. That is why secondly, an *in vitro* lesion model in which explants were pre-treated with IL1β before culture in chondrogenic medium was developed.

Different studies have shown that *in vivo* infiltration of IL1β into the joints results in degradation of Col and PGs from the chondrocyte ECM [@B13]. In our study, constructs showed lower amounts of PGs and less rounded cells after IL1β treatment than without treatment, except in CHS scaffolds. Scaffolds composed of CHS have been described as having better anti-inflammatory properties [@B14].

Regarding to the ICRS II scale, it was demonstrated lower inter- and intra-reader variability compared with other traditional scales. The overall assessment and matrix staining scores had the best correlation coefficients for inter- and intra-reader variability [@B8]. However, there are limitations of this study to take into account. It is necessary to consider any disadvantage of assessing the quality of repair in the *in vitro* developed models using the ICRS II scale, which was originally designed to evaluate *in vivo* osteochondral repair. ICRS II [@B8] was developed comprising 14 criteria: tissue morphology, matrix staining, cell morphology, chondrocyte clustering, surface architecture, basal integration, tidemark formation, subchondral bone fibrosis, inflammation, abnormal calcification, vascularization, surface assessment, mid/deep zone assessment and overall assessment. However, we focus on the assessment of 7 out of 14, which were related to chondrocyte phenotype and tissue structure. The assessment of the other 7 parameters was not possible in our developed model (tidemark formation, subchondral bone fibrosis, inflammation, abnormal calcification, vascularization, surface assessment and mid/deep zone assessment).

It is also relevant to point out that lack of mechanical stimuli negatively influences the quality of the neotissue formed. It is well known that continuous passive movement was shown to stimulate the repair of focal lesions with a neotissue similar to hyaline cartilage [@B9] and movement and loading in the joint were demonstrated to be essential for development and maintenance of normal cartilage structure [@B15]. The duration of our study was only two months, which is less time than that described in the literature. Because cartilage repair is a slow process, mathematical models have predicted that more than 18 months would be required to obtain complete cartilage maturation*in vivo* [@B5]. *In vitro* culture for long periods of time increases the risk of culture contamination and cartilage degradation [@B3]. However, our group had previously tested these two-month-culture-models without culture contamination or tissue degradation [@B16].

In conclusion, in an *in vitro* model using hBMSCs cultured on a Col I +Col II +HS scaffold displayed higher overall human cartilage lesion repair assessment than those of the other scaffolds. The capacity for repair by hBMSCs and the levels of construct chondrogenic phenotype of human cartilage lesions are lessened by pretreatment with IL1β.
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![**Histology of repair in human cartilage non interleukin- 1β-treated lesions (Non-IL) and IL1β-treated lesions (IL).** Hematoxylin-eosin (HE), Safranin O (SO) and Masson\'s Thricrome (MT) staining of the models. Scale bar 100µm (smaller images 200 µm). Col I: type I collagen; Col II: type II collagen; HS: heparan sulfate; CHS: chondroitin sulfate.](ijmsv14p1257g001){#F1}

![**Histology and immunohistochemistry of repair obtained using type I and II collagen and heparan sulfate scaffolds (Col I+Col II+HS), in non-interleukin-1β-treated lesions**. Images of Safranin O (SO) and Masson\'s Thricrome (MT) staining, and type I (Col I) and II (Col II) collagen and aggrecan (Agg) immunostaining performed on the neotissues formed on Col I+Col II+HS scaffolds in the Non-IL model. Col and Agg immunostaining were counterstaining with hematoxylin-eosin. Scale bar 100µm.](ijmsv14p1257g002){#F2}

###### 

Assessment of quality of repair in human cartilage non interleukin- 1β-treated lesions (Non-IL) and IL1β-treated lesions (IL). International Cartilage Repair Society II (ICRS II) scale values for different scaffolds in the Non-IL1β-treated and IL1β -treated model. Our modified scoring system comprises 7 of the 14 original parameters.

  ------------------------------------------------------------------------------------------------------------------------------------
  Parameter                Col I\     Col I (IL)   Col I +HS (Non-IL)   Col I\   Col I +\   Col I +\   Col I\          Col I\
                           (Non-IL)                                     +HS\     Col II\    Col II\    +Col II +CHS\   +Col II +CHS\
                                                                        (IL)     +HS\       +HS (IL)   (Non-IL)        (IL)
                                                                                 (Non-IL)                              
  ------------------------ ---------- ------------ -------------------- -------- ---------- ---------- --------------- ---------------
  Tissue morphology        30         5            35                   30       50         20         35              20

  Matrix staining          0          0            5                    0        50         5          15              0

  Cell morphology          15         0            5                    25       70         40         80              40

  Chondrocyte clustering   100        100          100                  100      100        100        100             100

  Surface architecture     90         80           80                   90       90         90         40              50

  Integration              30         5            60                   50       80         65         10              50

  Overall assessment       44%        31%          47%                  49%      73%        53%        46%             43%
  ------------------------------------------------------------------------------------------------------------------------------------

Col I: type I collagen; Col II: type II collagen; HS: heparan sulfate; CHS: chondroitin sulfat.
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